One assignee dominates this dataset, holding 77 of the 123 records in scope — well over half the field. The next four assignees combine for another 42 records, bringing the top five to 96.7% of all records. This level of concentration means most of the treatment-zone and lenslet-array design space is already claimed by a small number of parties, and any new filer needs to check their draft claims against the leader’s portfolio specifically, not just the field in general.

Filings peaked at 60 records in 2019, then dropped to a low base before climbing again — from 2 filings in 2021 to 9 in 2024, a +350% increase over that span. That is the most recent period that can be read reliably, because publication lags filing by roughly 18 months, so 2025 and 2026 figures are still incomplete and should not be read as a slowdown. Taken together, the pattern looks like renewed commercial interest following an earlier boom-and-bust cycle rather than a technology past its peak.

The overwhelming majority — 87.8% of the 123 records — touch IPC subclass G02C, covering spectacles and lens hardware, and 48.0% also touch A61F, which covers implants and prostheses framing for physiological treatment claims. Smaller branches include A61N (electrotherapy and radiation therapy, 10.6%) and thin coverage of diagnostics and healthcare informatics. This tells you the field is still primarily a physical lens-design claim space, with software-based monitoring and diagnostic integration comparatively under-claimed.